Introduction
Despite recent therapeutic gains, heart failure (HF) remains a major cause of mortality and of hospitalizations worldwide. Its prevalence has been put at approximately 1-2% of the adult population in developed countries; more recent forecasts alarmingly predict more than doubling of this prevalence.
1 -3 The therapeutic management of chronic HF, particularly for patients with reduced ejection fraction (HFrEF), is built mainly around drug combinations including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs) and diuretics. Recently, the international guidelines in Europe 1 and in the USA 4 for the treatment of HFrEF have been updated to include the use of sacubitril/valsartan [an angiotensin receptor-neprilysin inhibitor (ARNI)] and ivabradine (IVA; a sinus node I f channel inhibitor that reduces heart rate).
Over the last three decades, the implementation of guideline-recommended drug treatments for HFrEF has resulted in a decline of HF mortality, 5 but early post-discharge mortality and hospital readmission rates have remained stable or may even be worsening due to the complexity of multiple co-morbidities in ageing HF patients and to the lack of implementation of recommended medications or proper titration of these drugs. 6, 7 Network meta-analysis (NMA) and multiple treatment comparisons of randomized controlled trials (RCTs) facilitate the indirect comparisons of multiple interventions that have not been studied in head-to-head studies. These methods are attractive for clinical researchers because they seem to respond to their main concern: determining the best available intervention.
A recently published NMA of drug treatment for HFrEF 8 has emphasized the benefits of certain drug combinations over the last 30 years. However, by focusing only on all-cause mortality as an endpoint and not including all the recommended drug groups, the review does not fully reflect the burden of the disease and the options available. Thus, in order to provide a more comprehensive picture of the impact of therapy and in particular on the burden of hospitalizations, we reviewed all available evidence regarding the pharmacological treatment of chronic HFrEF including all guideline-recommended drug groups on the endpoints of all-cause mortality, cardiovascular mortality, hospitalization for HF and all-cause hospitalization.
Methods

Identification and selection of studies
The PubMed, EMBASE, and Cochrane CENTRAL databases were searched using a strategy adapted from the above mentioned review, 8 for the period January 2015 until May 2017. A search was made for the main drug groups for the treatment of HF (ACEIs, BBs, ARBs, MRAs) and the newer groups, including I f channel blockers (namely, IVA) and ARNI (namely, sacubitril/valsartan or LCZ696). Studies were considered if they were RCTs and comparisons of drug efficacy within the same drug group were excluded. The retrieved studies were added to the list of studies provided in reference 8; there was only one addition, the SHIFT trial of IVA. 9 The target studies were limited to those in adult outpatients (aged ≥18 years to 70 years) with chronic HFrEF (left ventricular ejection fraction <45%) of ischaemic or idiopathic aetiology. The review focused on studies conducted principally in North America or Europe. Excluded were studies where the entire population comprised patients with a concomitant diagnosis that was likely to have a major effect on endpoint attainment (e.g. acute HF, chronic obstructive pulmonary disease, diabetes mellitus, renal failure, coronary heart disease). The PRISMA diagram showing the search and selection of references is provided in the online supplementary Figure S1 , along with the list of references excluded on full text (Table S1) Information from the reports of the included studies was entered into a database (double entry with reconciliation). For each endpoint, the total number of events was extracted for each arm. The exposure time was the mean or median follow-up time if reported, or else the planned study duration. To account for concomitant therapy in the trials, treatments were categorized by drug group combination using a patient threshold of 50%; thus if >50% of the trial patients received concomitant drugs of interest (e.g. ACEI and BB), the treatment was described as a combination therapy (the study drug group + the concomitant drug group).
Network meta-analysis
Network meta-analysis is a statistical method that combines direct (i.e. head-to-head) and indirect evidence [i.e. via one or more common comparator(s)] in a mixed treatment comparison. 10 It therefore facilitates indirect comparisons of interventions that have not been studied in head-to-head studies. In such analyses, the treatments form a connected network, i.e. there is path from each treatment to every other treatment in the network. For consistency, we used the same methodology as in the previous NMA in HF, 8 with a modelling framework proposed by Dias et al. 11 This comprises a random-effects model within a Bayesian framework using R software and Winbugs 1.4. The model input was arm-level data, using the numbers of patients with at least one event at the end of the trial, the total number of patients randomized, and the mean or median follow-up duration (of the overall trial). The log mean follow-up time was used to transform the probability of an event into a constant rate for each trial arm by assuming an underlying Poisson process. A complementary clog-log (cloglog) link was used to model the event rates. Non-informative priors were used. Outputs from the model are presented as hazard ratios (HRs) for each treatment vs. placebo with 95% credible intervals (CrI) for the Bayesian probability that the treatment is better than placebo. Results were also computed for all pairwise comparisons.
Results
Study selection
A total of 58 RCTs were included, constituting the diagram presented in Figure 1 . This network forms a quasi-chronological progression of therapeutic advance starting from the top. Although many later studies compared their investigational treatment with standard of care, the analysis here is designed to calculate the treatment effect as compared with placebo (i.e. the absence of any of the studied drug groups).
The included trials were mostly multicentre, double-blind, placebo-controlled trials, although they varied considerably in terms of size and follow-up duration. Nine of the studies included less than 100 patients, whereas 11 included more than 2000. Follow-up durations ranged from 8 weeks, with 16 studies lasting 3 months or less, to 4 years, with 18 studies that were over 1 year. The severity of HF in the included patients ranged from mild in SOLVD-Prevent [with 66% New York Heart Association (NYHA) class I and 34% NYHA class II] to severe in CONSENSUS (with 100% NYHA class IV). The full list of studies is presented in the online supplementary material. The network was dominated by a few large-scale studies and these are listed in Table 1 . These Figure 1 The evidence network of studies reporting all-cause mortality. The thickness of the connecting lines corresponds to the number of patient-years of evidence (5 indicative thicknesses) for each drug group/combination comparison. The contributing studies are indicated in the adjoining panels with the number of randomized patients that contributed to the analysis in parenthesis and the cumulative total of patient-years of evidence. The online supplementary Figure S2 includes networks for the other endpoints investigated in this review. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BB, beta-blocker; MRA, mineralocorticoid receptor antagonist; IVA, ivabradine; PLC, placebo.
tended to be the more recent ones, reflecting the need to have larger studies to demonstrate the incremental benefit of added treatments.
When the study data are viewed in terms of patient-years of follow-up for the investigational arms of the included treatments (Figure 2A ), the weight of evidence provided by the larger study programmes is clear. It might also be noted that the HF indication for each of ARNI and IVA was informed by a single RCT. When the patient follow-up by drug group in this indication is considered ( Figure 2B) , it can be seen that the evidence is dominated by the studies of ARBs, BBs, ARNI and IVA.
. As might be expected given the variety in the included studies in terms of inclusion criteria, design and endpoint adjudication (all-cause mortality excepted), there is a significant amount of heterogeneity in the network for each endpoint, resulting in some uncertainty in comparative estimates. For example the heterogeneity parameter for all-cause mortality was between-study variability =0.17 (95% CrI 0.05-0.35); for all-cause hospitalizations this measure was slightly lower, but for other endpoints it was higher (online supplementary Table S2A ). The main results of the NMA for each drug group, or combination of groups, vs. placebo for each endpoint, are summarized in Table 2 . The results for each endpoint are also illustrated in forest plots (Figures 3-6) , which show the HR for each treatment with its 95% CrI. The full results of the NMA are presented in the online supplementary Figure S2 with a separate matrix for each endpoint. It should be noted that the comparisons are presented vs. placebo and do not necessarily emanate from an RCT; the NMA provides this placebo comparison in an indirect manner. All treatment groups or combinations were associated with some reduction in risk. The most efficacious treatment combinations vs. placebo are found at the top of the figures with the point estimates relatively far (to the left) from the null-effect indicator of 1.0.
In the forest plot for all-cause mortality ( Figure 3 superiority of the combination over placebo. The best combinations are ARNI+BB + MRA and ACEI+BB + MRA + IVA with a relative risk reduction of 62% and 59%, respectively. Of the triple therapies, the combination ACEI+BB + MRA results in a somewhat better result than ACEI+ARB + BB. In the forest plot for cardiovascular mortality (Figure 4) , the trend in HR estimates is quite similar to those already described for all-cause mortality, with the exception of BB monotherapy, which did not appear to perform so well on this endpoint. The CrIs are wider for this comparison than all-cause mortality because fewer studies reported this endpoint (n = 41).
The data for all-cause hospitalization are presented in Figure 5 . The best performing combinations appear once again to be ARNI+BB + MRA and ACEI+BB + MRA + IVA (relative risk 
Figure 4 Forest plot of hazard ratios (HR) and their 95%
credible intervals for cardiovascular mortality (random-effects model without adjustment). The point estimates with a value <1 signify a relative superiority of the active treatment and the whiskers mark the limits of the 95% credible interval. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BB, beta-blocker; IVA, ivabradine; MRA, mineralocorticoid receptor antagonist.
The pairwise comparisons of all treatments (and treatment combinations), for each endpoint, are provided in the online supplementary Table S2 . The matrices indicate the estimated treatment effect (and CrI) for each treatment pair along with the Bayesian probability that one is better than the other. The hierarchy of treatment combinations vs. single treatment group comparators was very similar to the comparisons vs. placebo. For each endpoint, there was little difference in efficacy between the most effective combinations: for all-cause death, HRs for ACEI+BB + MRA + IVA Figure 5 Forest plot of hazard ratios (HR) and their 95% credible intervals for all-cause hospitalization (random-effects model without adjustment). The point estimates with a value <1 signify a relative superiority of the active treatment and whiskers mark the limits of the 95% credible interval. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BB, beta-blocker; MRA, mineralocorticoid receptor antagonist. credible intervals for hospitalization due to worsening heart failure (random-effects model without adjustment). The point estimates with a value <1 signify a relative superiority of the active treatment and the whiskers mark the limits of the 95% credible interval. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BB, beta-blocker; IVA, ivabradine; MRA, mineralocorticoid receptor antagonist. 
Discussion
Our results, based on the analysis of relevant clinical trials conducted between 1987 and 2017, show that the combination of disease-modifying medications, i.e. ACEIs, ARBs, BBs, MRAs, IVA and ARNI, resulted in the progressive improvement over the last 30 years in mortality and hospitalization outcomes in HFrEF. This improvement may be visualized, for each of the endpoints studied, by the leftward progression of the point estimates, with intensifying combinations of drug groups. Overall, our NMA validates the recommendations made by international guidelines. Among the different possible combinations, those including the most recently developed drugs, IVA and sacubitril/valsartan are among the most efficacious: ARNI+BB + MRA and ACEI+BB + MRA + IVA tended to be the combinations associated with the lowest point estimates of HR vs. placebo for the mortality endpoints and for hospitalizations. There was a relative risk reduction of 62% and 59%, respectively, on all-cause death, 64% and 59% on cardiovascular deaths, 42% and 42% on all-cause hospitalizations, and 73% and 75% on hospitalizations for worsening HF. However, none of these estimates can be taken as strong evidence of superiority over other combinations and it is clear that the options need to be carefully weighed given the characteristics of the individual patient. Numerous factors including rhythm (sinus or atrial fibrillation), heart rate at baseline, low systolic blood pressure, severe kidney disease can influence the choice of ARNI or IVA as third-line therapy in HFrEF based on the respective indication and contraindication of each drug. However, this combination of the two drugs is recommended by the European Society of Cardiology (ESC) guidelines if the patient's profile fits.
While individual RCTs are not always easy to compare given the differences in the entry criteria, recent analyses have concluded that the proportion of deaths adjudicated as cardiovascular has decreased over the last 30 years. 12, 13 The noteworthy effect of the combinations of disease-modifying therapies observed in the clinical trials included in this analysis may however not fully translate to the real-life situations due to the inherent selection bias of patients enrolled in randomized trials whereas observational studies show that HF patients usually have a constellation of co-morbidities and are generally older than those studied in clinical trials.
14 However, it has been shown that adherence to guideline-recommended therapies is associated with improved outcomes in observational studies.
14 The results of the meta-analysis should therefore encourage physicians to apply the most efficacious combinations of HF medications.
The recent ESC guidelines emphasize the need to reduce the burden of hospitalizations and rehospitalizations as one of the major goals of the management of HFrEF 1 and the importance of this goal has been recently highlighted in a position paper regarding the conduct of future HF trials.
15 Therefore, our analysis included not only mortality data but also all-cause hospitalizations and HF hospitalizations together with the totality of available drugs tested in RCTs. It therefore extends the results of a previous meta-analysis to hospitalizations and finds a similar stepwise improvement of all-cause death and of HF hospitalizations by modern combinations.
The review has a number of limitations. The start date for the literature search (January 1987) was arbitrary and chosen to capture a 30-year time span. This choice resulted in the omission of a few potentially relevant studies, notably some earlier captopril trials. Some important trials in high-risk cardiovascular patients were excluded because of the decision to focus on patients with established HF. Thus the trials, SAVE, 16 AIRE 17 and HOPE, 18 which were important in establishing ACEIs as standard of care in patients at high cardiovascular risk or post-myocardial infarction, were not included in the analysis. A large number of small short-term studies (often designed to investigate drug effects on biomarkers or exercise tolerance) were included in the review, which may have introduced spurious information since the mean mortality rates were relatively higher in these than in the longer-term trials (e.g. 0.16 deaths per patient-year in 3-month trials vs. 0.07 deaths per patient-year in trials lasting >30 months). The review included treatments which do not have an indication in HF, namely: benazepril, imidapril, spirapril, telmisartan, celiprolol, bucindolol, atenolol, and canrenone, since the focus was on the drug groups only. Prescription of drugs with certain groups and not dosage used was considered for this analysis. This approach may have diluted the treatment effect of drugs with the indication. Our meta-analysis was based on the recommended add-on or substitution strategy and did not address other potential strategies such as ACEI+MRA + IVA, ARNI+IVA or ARNI+BB + digoxin, which might only be validated by properly designed clinical trials. It should also be noted that the patients enrolled in RCTs may not represent the real-life situation by being relatively younger and having fewer co-morbidities. Finally, since 30 years separate the oldest and the most recent trials included in our analysis, it is possible that the profile and the environment of patients enrolled in these trials have changed significantly over time. The statistical analysis of the retrieved data indicates a fairly large amount of uncertainty for several of the comparisons, reflecting the limitations already mentioned.
In conclusion, our analysis of relevant clinical trials published between 1987 and 2017 shows that the incremental use of combinations of disease-modifying therapies, i.e. ACEIs, ARBs, BBs, MRAs, IVA and ARNI, has resulted in the progressive improvement over the last 30 years in mortality and hospitalization outcomes in HFrEF. Our findings, illustrating the success of disease-modifying combinations, support the guideline recommendations.
Supplementary Information
Additional supporting information may be found online in the Supporting Information section at the end of the article. Figure S1 . The PRISMA flow diagram showing the results of the literature search and the selection of relevant studies. Figure S2 . The evidence networks of studies reporting endpoints other than all-cause mortality. (A) Cardiovascular death, (B) all-cause hospitalizations, and (C) hospitalizations due to worsening heart failure. Table S1 . List of references excluded on full text. each pairwise comparison, in the hazard ratio of the endpoint concerned. The point estimate and associated 95% credible intervals are provided. The adjacent box provides the probability estimate that the row-defined treatment is better than the column-defined treatment. At the foot of each table is the estimate of the heterogeneity parameter (i.e. between-study variability) SD. (A) All-cause mortality, (B) cardiovascular death, (C) all-cause hospitalizations, and (D) hospitalizations due to worsening heart failure.
